ACE inhibitors may slow cognitive decline
Cork, Ireland and Hamilton, ON - Centrally acting ACE inhibitors reduce the rate of cognitive decline in patients with dementia, regardless of blood-pressure levels at the time of their hypertension diagnosis, a new study has found
Some antihypertensives linked to breast-cancer risk
Boston, MA - The first observational study of long-term antihypertensive use and breast-cancer risk found that calcium-channel blockers (CCBs) were associated with a more than twofold increased risk, while ACE inhibitors appeared to be associated with a reduced risk.
Early surgery bests "watchful waiting" in severe MR patients without symptoms
Rochester, MN - Patients with severe mitral regurgitation (MR) without a class I indication for surgical intervention fared significantly better when treated with surgery than patients who underwent "watchful waiting" while treated with medical therapy, according to the results of a new analysis, published in the August 14, 2013 issue of the Journal of the American Medical Association
Who, what, when? Questions over Heartware ENDURANCE trial
Framingham, MA - One of the principal investigators for the pivotal ENDURANCE trial testing HeartWare International’s ventricular-assist device (VAD) as destination therapy says he still plans to present the full results late next year.
Physician continuity important in reducing HF outcomes
Edmonton, AB - Patients hospitalized with heart failure have significantly better clinical outcomes if they are followed up with a physician early after hospital discharge, a new study shows [1]. Physician continuity, however—defined as seeing a doctor already familiar with the patient—was associated with significantly better outcomes than seeing an unfamiliar physician.
Journal “Metabolism and somatic diseases”
“Metabolism and somatic diseases” is a medical journal for specialists in different fields of medicine – from internal medicine to interventional cardiology, from basic science to engineering of medical equipment . The journal is published four times a year in two languages (English and Russian) in printed and electronic forms. Printed version is available for free. All issues of journal are available for free on official website www.cardioprogress.ru
AMPLIFY: Apixaban in acute VTE as effective but safer than standard anticoagulation
Amsterdam, the Netherlands - The oral factor Xa inhibitor apixaban (Eliquis, Pfizer/Bristol-Myers Squibb) was as effective as standard enoxaparin plus warfarin in treating acute venous thromboembolism (VTE) in a large randomized trial, one in which treatment with apixaban also led to a 69% drop in risk of major bleeding complications
FDA refuses rivaroxaban stent-thrombosis indication for now
Raritan, NJ - The FDA has given a complete response letter (CRL) to one of the companies behind rivaroxaban (Xarelto, Bayer Pharma/Janssen Pharmaceuticals) indicating that it won"t, for now, approve the oral factor Xa inhibitor for prevention of stent thrombosis in patients with acute coronary syndromes
Electronic cigarettes as good as patch for quitting smoking
Barcelona, Spain - Electronic cigarettes are as effective as the patch when it comes to helping smokers overcome the cravings of nicotine addiction, suggests the first randomized study of its kind.
***
news 1
The Scientific Committee begins accepting abstracts and applications for the scientific program of the XI International Forum of Cardiology and Internal Medicine
Dear Colleagues!
We invite you to take part in XI International Forum of Cardiology and Internal Medicine. Forum will take place on 22-24 March 2022 in Moscow (online).
Analysis of the activities of the "Cardioprogress" foundation: results of 2021
Dear colleagues!
In 2021, a number of significant events took place in cardiology.
Due to the continuation of restrictive measures, most scientific events were organized online. This required adaptation and the acquisition of new skills. However, all planned events took place.
Professor David Wood, WHF President, on participating in the 70th World Health Assembly
Today marks the opening of the 70th World Health Assembly (WHA), one of the highlights of the global health calendar. At this annual conference, Ministers of Health, civil society and World Health Organization (WHO) experts will meet to discuss the most pressing health issues of our time, including cardiovascular disease (CVD).
As President of the World Heart Federation, I am delighted to welcome a large delegation of member partners, members, Board and staff to the event. Through our leading position in cardiovascular health, we aim to raise the profile of CVD to ensure that global health policies meet the needs of patients and our global membership.
Genetic Risk Could Guide Heart Disease Prevention
The use of genetic sequencing to identify which patients would benefit most from aggressive statin therapy for the primary prevention of a heart attack could soon be a clinical reality. And the discovery of genetic mutations associated with cardiovascular disease — but not linked to any known risk factors — opens the possibility of novel therapies to help people cut the risk for future events.
"Among those at high genetic risk, statins confer a greater benefit for primary prevention of coronary heart disease," said Sekar Kathiresan, MD, from Massachusetts GeneralHospital in Boston and the Broad Institute in Cambridge.
On behalf of Cardioprogress Foundation let us sincerely congratulate you with the World Heart Day!
On behalf of Cardioprogress Foundation let us sincerely congratulate you with the World Heart Day!
World Heart Day is celebrated annually starting from 1999, more than in 100 countries around the globe in the last Sunday of September. And in 2011, the World Heart Day. And from 2011 it has its own confirmed date- the 29th of September. Events, that take place during the World Heart Day are attract attention to the problem of cardiovascular diseases, it"s the world"s biggest intervention against these conditions. It’s utterly important to show the world the importance of healthy life style, and the influence of bad habits on the cardiovascular system.
Trump Pick for CMS Would Ease Up on Physicians
Seema Verma, MPH, President Donald Trump"s choice to head the Centers for Medicare & Medicaid Services (CMS), has mixed feelings about electronic health record (EHR) systems. It"s just one example of how she"s on the same page with many physicians regarding healthcare. "My doctor…is staring at her computer instead of looking at me," the healthcare policy consultant told the US Senate Committee on Finance during her confirmation hearing yesterday.
Verma"s comment came in response to a question about the future of the CMS incentive program for meaningful use of EHRs, much criticized by physicians for turning them into data entry clerks. She also recounted seeing signs in physician waiting rooms that apologized for schedule delays due to EHR implementation. Yet another tech challenge she cited was the lack of EHR interoperability, which prevents different programs from freely exchanging data.
Mediterranean Diet With Olive Oil Boosted HDL Function?
More research suggests that a Mediterranean-style diet supplemented with either virgin olive oil or mixed nuts enhances the function of HDL cholesterol[1].
In a subset of 296 patients at high risk of heart disease in thePREDIMED study, cholesterol efflux capacity (CEC), the first step in reverse cholesterol transport, was significantly increased at 1 year compared with baseline in those advised to eat a Mediterranean diet rich in virgin olive oil (VOO) (P=0.018) or mixed nuts (P=0.013) rather than a reduced-fat diet.
International Heart and Vascular Disease Journal-Issues
International Heart and Vascular Disease Journal
RU
EN